According to Zacks, “Regeneron reported disappointing top-line data from an ongoing phase II CAPELLA study, evaluating Eylea in combination with rinucumab, in patients with neovascular age-related macular degeneration (wet AMD). Given that the company is looking to expand Eylea’s label into additional indications, the reported study results are unimpressive. We note that Eylea, which is approved for several eye disorders, is the key growth driver at Regeneron. The company expects U.S. Eylea net sales to grow 20–25% year over year in 2016. Meanwhile, Regeneron’s efforts to develop its pipeline are impressive. The company has several candidates in its pipeline with blockbuster potential. Investor focus should remain on the approval status of Dupixent and sarilumab. Also, Regeneron’s collaboration deals with companies like Bayer and Sanofi are encouraging. Regeneron got a huge boost when Praluent became the first PCSK9 inhibitor to gain FDA nod.”
A number of other equities research analysts have also issued reports on the company. Goldman Sachs Group Inc. restated a buy rating and issued a $521.00 price target on shares of Regeneron Pharmaceuticals in a research report on Tuesday, September 27th. Jefferies Group restated a hold rating on shares of Regeneron Pharmaceuticals in a research report on Wednesday, August 17th. Vetr lowered Regeneron Pharmaceuticals from a strong-buy rating to a buy rating and set a $419.76 price target for the company. in a research report on Monday, July 11th. Chardan Capital lowered Regeneron Pharmaceuticals to a sell rating and set a $325.00 price target for the company. in a research report on Wednesday, June 8th. Finally, Leerink Swann restated a buy rating and issued a $530.00 price target on shares of Regeneron Pharmaceuticals in a research report on Wednesday, September 21st. One analyst has rated the stock with a sell rating, fourteen have assigned a hold rating and eleven have issued a buy rating to the stock. The company has a consensus rating of Hold and an average price target of $480.09.
Regeneron Pharmaceuticals (NASDAQ:REGN) opened at 390.06 on Tuesday. The firm’s 50-day moving average price is $401.81 and its 200 day moving average price is $391.84. The stock has a market capitalization of $40.81 billion, a P/E ratio of 60.85 and a beta of 1.31. Regeneron Pharmaceuticals has a 12-month low of $329.09 and a 12-month high of $592.59.
Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings results on Thursday, August 4th. The biopharmaceutical company reported $2.82 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.65 by $0.17. The business earned $1.21 billion during the quarter, compared to analyst estimates of $1.24 billion. Regeneron Pharmaceuticals had a return on equity of 23.77% and a net margin of 15.65%. The business’s revenue was up 21.4% compared to the same quarter last year. During the same period in the prior year, the business earned $2.89 earnings per share. On average, equities analysts anticipate that Regeneron Pharmaceuticals will post $11.02 EPS for the current year.
In related news, Director Joseph L. Goldstein sold 2,125 shares of the firm’s stock in a transaction dated Friday, July 29th. The stock was sold at an average price of $425.00, for a total transaction of $903,125.00. Following the transaction, the director now owns 15,125 shares of the company’s stock, valued at $6,428,125. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Company insiders own 10.40% of the company’s stock.
Several institutional investors have recently added to or reduced their stakes in the company. Meiji Yasuda Asset Management Co Ltd. raised its position in Regeneron Pharmaceuticals by 1.2% in the first quarter. Meiji Yasuda Asset Management Co Ltd. now owns 852 shares of the biopharmaceutical company’s stock worth $307,000 after buying an additional 10 shares in the last quarter. Wetherby Asset Management Inc. raised its position in Regeneron Pharmaceuticals by 2.3% in the second quarter. Wetherby Asset Management Inc. now owns 796 shares of the biopharmaceutical company’s stock worth $278,000 after buying an additional 18 shares in the last quarter. Fagan Associates Inc. raised its position in Regeneron Pharmaceuticals by 2.5% in the second quarter. Fagan Associates Inc. now owns 820 shares of the biopharmaceutical company’s stock worth $286,000 after buying an additional 20 shares in the last quarter. American Money Management LLC raised its position in Regeneron Pharmaceuticals by 3.3% in the second quarter. American Money Management LLC now owns 785 shares of the biopharmaceutical company’s stock worth $274,000 after buying an additional 25 shares in the last quarter. Finally, Cleararc Capital Inc. raised its position in Regeneron Pharmaceuticals by 1.4% in the first quarter. Cleararc Capital Inc. now owns 1,909 shares of the biopharmaceutical company’s stock worth $688,000 after buying an additional 26 shares in the last quarter. 68.16% of the stock is currently owned by hedge funds and other institutional investors.
Regeneron Pharmaceuticals Company Profile
Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company’s segment includes activities related to the discovery, development and commercialization of pharmaceutical products for the treatment of serious medical conditions.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Regeneron Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.